Pretreatment features and risk of death from BRAF-positive metastatic melanoma patients treated with vemurafenib.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e21028
Abstract: e21028Background: Clinicopathologic features of BRAF-positive metastatic melanoma patients were identified. No study to date has examined influence on risk of death features at baseline before starting treatment with vemurafenib. The purpose of the study is… read more here.
Keywords: melanoma; braf positive; death; metastatic melanoma ... See more keywords